中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2014年
15期
63-64,67
,共3页
罗格列酮%非肥胖%2型糖尿病%脂肪肝%疗效观察
囉格列酮%非肥胖%2型糖尿病%脂肪肝%療效觀察
라격렬동%비비반%2형당뇨병%지방간%료효관찰
Rosiglitazone%Non-obese%T2DM%NAFLD%Clinical observation
目的：观察罗格列酮治疗非肥胖2型糖尿病（T2DM）合并非酒精性脂肪肝(NAFLD)的疗效。方法：对102例合并NAFL的非肥胖2型糖尿病患者进行随机分组，即A组（基础治疗组+罗格列酮药物组）和B组（基础治疗组），随访24周，观察两组患者治疗前后体重指数、血糖、餐后2小时血糖、肝功、血脂、胰岛素、HOMA-IR、肝脏影像学等变化并进行对比研究。结果：加用罗格列酮组治疗后，其Fins、AST、ALT、HoMA-IR较治疗前明显改善，TG较前好转；基础治疗组Fins、AST、ALT、TG、HoMA-IR指标有好转趋势，但无统计学差异；加用罗格列酮组治疗优于基础治疗组。结论：加用胰岛素增敏剂能明显改善胰岛素抵抗、肝脏酶学及影像学指标，也证明了胰岛素抵抗在非酒精性脂肪肝的发生和发展中起着重要的作用，罗格列酮可有效逆转 NAFLD，可能为非肥胖T2DM并NAFL组提供临床治疗参考。
目的：觀察囉格列酮治療非肥胖2型糖尿病（T2DM）閤併非酒精性脂肪肝(NAFLD)的療效。方法：對102例閤併NAFL的非肥胖2型糖尿病患者進行隨機分組，即A組（基礎治療組+囉格列酮藥物組）和B組（基礎治療組），隨訪24週，觀察兩組患者治療前後體重指數、血糖、餐後2小時血糖、肝功、血脂、胰島素、HOMA-IR、肝髒影像學等變化併進行對比研究。結果：加用囉格列酮組治療後，其Fins、AST、ALT、HoMA-IR較治療前明顯改善，TG較前好轉；基礎治療組Fins、AST、ALT、TG、HoMA-IR指標有好轉趨勢，但無統計學差異；加用囉格列酮組治療優于基礎治療組。結論：加用胰島素增敏劑能明顯改善胰島素牴抗、肝髒酶學及影像學指標，也證明瞭胰島素牴抗在非酒精性脂肪肝的髮生和髮展中起著重要的作用，囉格列酮可有效逆轉 NAFLD，可能為非肥胖T2DM併NAFL組提供臨床治療參攷。
목적：관찰라격렬동치료비비반2형당뇨병（T2DM）합병비주정성지방간(NAFLD)적료효。방법：대102례합병NAFL적비비반2형당뇨병환자진행수궤분조，즉A조（기출치료조+라격렬동약물조）화B조（기출치료조），수방24주，관찰량조환자치료전후체중지수、혈당、찬후2소시혈당、간공、혈지、이도소、HOMA-IR、간장영상학등변화병진행대비연구。결과：가용라격렬동조치료후，기Fins、AST、ALT、HoMA-IR교치료전명현개선，TG교전호전；기출치료조Fins、AST、ALT、TG、HoMA-IR지표유호전추세，단무통계학차이；가용라격렬동조치료우우기출치료조。결론：가용이도소증민제능명현개선이도소저항、간장매학급영상학지표，야증명료이도소저항재비주정성지방간적발생화발전중기착중요적작용，라격렬동가유효역전 NAFLD，가능위비비반T2DM병NAFL조제공림상치료삼고。
Objective: To observe the efficacy of rosiglitazone in the treatment of non-obese T2DM with NAFLD. Methods:102 cases of non-obese T2DM with NAFLD were randomly divided into groups, Group A( basic treatment group and group treated with rosiglitazone) and Group B(basic treatment group), followed up for 24 weeks. The changes of body mass index, blood glucose, 2-hour postprandial blood glucose, liver function, blood lipid, insulin, HOMA-IR, liver imaging before and after treatment were observed and comparatively researched. Results:after treatment of rosiglitazone, Fins、AST、ALT、HoMA-IR were obviously improved, TG was much better than before;the indicators of Fins、AST、ALT、TG、HoMA-IR in the basic treatment group tended to be improved but without significant difference;the efficacy of group with rosiglitazone was better than that of the basic treatment group. Conclusion:The treatment with insulin sensitizer can not only significantly improve insulin resistance, liver enzyme and imaging indexes, also proved that insulin resistance plays an important role in the occurrence and development of nonalcoholic fatty liver. Rosiglitazone can effectively reverse NAFLD, providing clinical reference for the treatment of non-obese T2DM with NAFLD.
